Trials / Recruiting
RecruitingNCT06905301
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 240 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor (AI). The purpose of the app is to increase adherence to treatment by informing patients about the risks of relapse and adverse event prevention and treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ribociclib | CDK4/6 inhibitor |
| DRUG | Letrozole | Aromatase inhibitor |
| DRUG | Anastrozole | Aromatase inhibitor |
Timeline
- Start date
- 2026-01-23
- Primary completion
- 2029-12-31
- Completion
- 2029-12-31
- First posted
- 2025-04-01
- Last updated
- 2026-04-01
Locations
6 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT06905301. Inclusion in this directory is not an endorsement.